genetically marked syngeneic T lymphocytes

Genetically marked syngeneic T lymphocytes are a form of cell therapy in which a patient's own (syngeneic) or an identical twin's (in the case of humans) T cells are collected, activated and expanded ex vivo, and then genetically modified to introduce unique genetic markers or therapeutic genes. These modifications can include the insertion of marker genes (such as neoR for tracking), suicide genes (like HSV-tk for safety control), or chimeric antigen receptors (CARs) targeting specific antigens such as CD19 or VEGFR-2. The primary mechanism involves adoptive transfer—infusing these engineered cells back into the patient to enhance immune function, target malignancies, or restore immunity after treatments like hematopoietic stem cell transplantation. This approach has been studied in contexts including HIV infection (to restore immune function in immunodeficient patients using gene-marked twin donor cells), hematologic malignancies (e.g., CAR-T therapies against B-cell cancers), and solid tumors by targeting tumor vasculature with CAR-modified T cells[2][3][5][7]. The genetic marking allows for tracking persistence and survival of infused cell populations.

Other names

gene-marked syngeneic T cellsgenetically modified syngeneic T lymphocytesgene-marked autologous/syngeneic T cells